Loading company…
Neomorph develops molecular glue degraders and other targeted protein degradation therapies.
Founded in 2020 and based in San Diego, US, Neomorph develops targeted protein degradation drugs for oncology and other disease areas. In April 2026, it raised USD 100 million in Series B funding led by Deerfield Management, with Regeneron Ventures, Longwood Fund, Alexandria Venture Investments and Binney Street Capital participating.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in